Language version

Health

New Study Reveals Russian Vaccine Less Effective Against South African Variant

Advertisement

Published

on

 Russia’s Sputnik V coronavirus vaccine appears significantly less effective in combating the South African variant of the virus, a new laboratory study of 12 cases has shown.

Scientists in the U.S. used blood samples from Argentinians who had been vaccinated with Sputnik V to investigate whether the antibodies they had produced would effectively fight various mutations of the virus which have been designated “variants of concern” by the global health community.

The researchers found that the immune response produced against variant B1.351 — the strain first identified in South Africa — was “markedly reduced” compared with the reaction to the initial coronavirus strains.

Sputnik V was also less effective in combating all variants with the E484K mutation — a specific mutation, nicknamed “Eek” by some scientists, which is present in the South African and Brazilian variants of the virus, and has recently been discovered in the U.S. and Japan.

“Sera from Sputnik vaccine recipients in Argentina had a median 6.1-fold and 2.8-fold reduction in neutralizing potency against B.1.351 and the E484K mutant spike, respectively,” the study said.

In eight of the 12 cases — 67% — the researchers found antibody responses that were “indicative of a failure to neutralize” against the South African variant, pointing to “markedly reduced neutralization titers” in the blood samples.

The results appear to contradict earlier statements by Russia’s health watchdog that claimed Sputnik V provided effective protection against variants of the virus.

No research into the effectiveness of the Sputnik V vaccine against virus mutations in the real world has been published.

The researchers added that Sputnik V was “likely to retain strong efficacy at preventing severe Covid-19, even in the case of infection by variants of concern,” but said their data pointed to a “concerning potential of B1.351 [the South African strain], and to a lesser extent, any variant carrying the E484K substitution, to escape the neutralizing antibody responses that this immunization elicits.”

This study — led by researchers at the Icahn School of Medicine at Mount Sinai in New York — was based on laboratory analysis using blood from 12 people who had been vaccinated with Sputnik V.

The AstraZeneca vaccine, which is based on similar adenovirus technology to Sputnik V, has also previously been found to deliver less effective protection against mild and moderate infections from the South African variant, although in a clinical trial with 2,000 participants there were no reported severe cases, suggesting vaccines may still be effective in preventing hospitalizations and deaths.

The study into Sputnik V also found that the jab appeared to be effective in preventing infection with the British variant of the virus — with antibody responses at a similar level to those noted in the peer-reviewed research into Sputnik V’s overall effectiveness, which was conducted and published before virus mutations had been identified.

The Sputnik V jab was found to have 91.6% efficacy against Covid-19 in a paper published in The Lancet.

The British variant has shown faster transmissibility rates — becoming the dominant strain of the virus in the U.K. and many other European countries — as well as higher mortality rates.

The head of Russia’s Rospotrebnadzor consumer watchdog, which is leading the country’s response against the pandemic, said only six cases of the South African variant have been detected in Russia.

In an interview with the Izvestia newspaper, Anna Popova added that 81 cases of the British variant have been detected.

She also warned Russians against unnecessary travel and said border closures had helped keep mutations of the coronavirus largely out of Russia.

“Since the Sputnik vaccine is now widely in use not only in Russia, but also in countries like Argentina, Chile, and Hungary, where some of the variants of concern … are more widespread, it is critical to assess the neutralizing activity of Sputnik vaccine-elicited antibody responses against these variants and mutant spikes,” the researchers noted.

Argentina’s president, who was vaccinated with Sputnik V, tested positive for the coronavirus over the weekend. He was experiencing only mild symptoms, which his doctors credited to having received the jab.

Science

US Hates Vaccine Passports, Europe Loves Them

Back in 1992, Yiannis Klouvas converted an old cinema into the Blue Lagoon restaurant, which garnered a strong reputation for live music. There is no music now.

The business, like so many others on the Greek island of Rhodes, is struggling due to the pandemic’s restrictions on travel.

“If we see a tourist on the street these days,” he says, “we take a photo to remember them.”

Mr. Klouvas is now banking on the EU Digital COVID Certificate, also known as the “green passport,” to save the summer.

Starting July 1, all EU member states will accept the certificates as proof of COVID-19 vaccination, a recent negative test, or recovery from the disease.

The plan got a resounding yes at the European Parliament on June 9. All EU member states, Liechtenstein, and Norway will implement the passport.

But across the Atlantic, the idea faces strong head winds, whether for travel or domestic use. The Biden administration has ruled out introducing vaccination passports, and some states even ban them.

Fox News talk show host Tucker Carlson likened the use of them to segregation. “Medical Jim Crow has come to America,” he said.

Prioritizing freedom and fears of government overreach underpin the rejection of vaccine certificates in the U.S., while European societies have grappled more with issues of privacy and fairness.

And so as Western countries savor a return to the old, this phase of post-pandemic mobility is being shaped by cultural attitudes – like Europeans’ tendency to make the most of having entirely different cultures within a few hours’ drive – and the initial responses to the pandemic.

“Alabama never closed the border to Mississippi in the way Finland closed the border to Sweden,” points out Anders Herlitz, a researcher at Sweden’s Institute for Futures Studies.

“Here in the EU, the vaccine passports are seen as a necessary evil to get rid of other, much more extensive, limitations to people’s freedom, whereas in the U.S., they would not help getting rid of other limitations, but only cause new limitations.”

Jen Kates, director of global health and HIV policy at the Kaiser Family Foundation in Washington, says previous pandemic plans didn’t account for cultural variations and responses.

“One thing we know from how COVID has played out globally is that culture matters,” she says. “Politics, culture, all the differences that we know that structure people’s lives have to be taken into account, both for getting back to normal and for preparing for the next pandemic.”

Europe’s green passport

Nine European countries, including Greece and Germany, are already using the EU COVID-19 passport. When the Greek government unveiled the passport, Prime Minister Kyriakos Mitsotakis trumpeted the opening of a “fast lane” to facilitate travel.

Everyone realises two years without tourists would be an economic disaster for the Mediterranean nation.

“Greece is very strongly pro-vaccine passport, especially as far as foreigners are concerned,” says Paris Kyriacopolous, chairman of Motodynamics and Lion Rental, which operates Sixt Rent a Car in Greece.

Ipsos polling data suggests the dominant attitude toward COVID-19 vaccine passports across Europe is equally positive.

When it comes to using them domestically, citizens are more concerned by questions of fairness than by privacy issues, and pockets of society are ambivalent about or opposed to vaccines. But when it comes to travel, the view is clearly pro.

Even Germany, which had more rigorous ethical debates on the issues and boasts stringent data privacy laws, got behind the idea of digital health certificates.

More than 60% of Germans now support implementing them, according to a recent YouGov poll, even though less than half the population has had a first jab.

Malcolm Jorgensen, an academic who is providing administrative assistance at one of Berlin’s six vaccination centres, is fully vaccinated as of this week.

His vaccination card has allowed him to shop at markets and visit the gym without flashing a coronavirus test result. He says the move from a paper card to a digital passport isn’t much of a leap.

“There’s already informal digitization,” says Dr. Jorgensen. “At the gym I can just show a photograph of my vaccination booklet, rather than the booklet itself. Digitization is inevitable.”

In Germany, debates over the passports have had less to do with privacy concerns than with equity of access for people who choose not to or cannot be vaccinated. Analysts note that medical insurance companies already have individuals’ health details.

“It’s an ethical question,” says Olga Stepanova, a data protection attorney with WINHELLER Law. “Each government needs to decide what kinds of access limitations may be imposed to protect others, while not limiting freedoms of non-vaccinated people in an inappropriate way.”

Concern about privacy

The freedom debate has been particularly fierce in the U.S. Much like other issues throughout the pandemic, the vaccine certificate has become deeply polarizing.

The divisions fall along partisan lines – just as they did with stay-at-home orders and mask mandates – and so different states have moved toward normalcy in distinct ways.

New York was the first to introduce its Excelsior Pass, which allows residents to prove their vaccination status to gain access to certain social venues. But several states, including Florida and Texas, ban such passes outright.

The state of Michigan has been one of the most closely watched during the last year, ever since former President Donald Trump notoriously tweeted “Liberate Michigan” last spring in regard to tough anti-lockdown measures implemented by Democratic Gov. Gretchen Whitmer.

This spring, as the state coped with one of the worst spikes of COVID-19, a bitter debate over vaccine passports broke out.

This month the Michigan House approved legislation to ban so-called vaccine passports in the state – even though the governor has repeatedly said she has no intention of introducing them.

“The threat of government controlling one’s daily life through identification of whether one is immunised or not is frightening,” said Rep. Sue Allor, who proposed the bill.

Like the rest of the country, the state is divided. The University of Michigan has mandated that students living in dormitories must prove vaccination.

Since Michigan is a border state, some Democrats have pushed for passes as a way to travel more easily to Canada and avoid quarantines.

Dave Boucher, a government and politics reporter with the Detroit Free Press, says opposition centers around freedom of choice. It’s about “the government ‘telling me what I can and can’t do,’” he says.

“And there’s always the slippery slope argument where if the government is endorsing vaccine passports now, then they’re going to get vital information about you and track that information and use it in unknown, nefarious ways.”

Rich Studley, president and CEO of the Michigan Chamber of Commerce, says the vast majority of his members are committed to a safe reopening and return to normal, but don’t see passports as a way to do it.

“There is no groundswell of support that would be in favor of mandatory vaccines and vaccine passports,” he says.

“If there is one thing businesses have learned over the past year in Michigan, other than how to survive, it is how to operate their business safely to protect employees and customers.”

In general, Americans – much like Europeans – are more accepting of passports to travel than they are for domestic use, according to polls. Some analysts believe they are an inevitable part of post-pandemic mobility.

“Digital health certificates are already available in the EU, and my guess is that they will be widely used, even without being adopted by the U.S.,” says Chris Dye, a professor of epidemiology at Oxford University in Britain.

As other parts of the world move forward with passes, the U.S. might find itself playing catch-up. “It’ll be really interesting to look ahead three to six months and see as other parts of the world are going forward and using these kinds of mechanisms, if there will be a change,” says Dr. Kates.

First Published in Christian Science Monitor

Continue Reading

CORONA VIRUS

Rwanda Uses Trained Dogs To Detect Covid-19 Patients

Published

on

Passengers arriving at Kigali International Airport in Rwanda can now be tested for COVID-19 without inserting swabs into their nose or throat to collect lab samples and wait for minutes to receive results.

Instead, the airport is using trained sniffer dogs to detect Covid-19 by smelling sweat samples taken from passengers with just cotton patches. The collected samples are then taken to the sniffing cabin set up in a separate area.

With an accuracy close to that of a PCR test in about one minute, a dog quickly detects which of the samples in the cabins has COVID-19.

This initiative was launched on Friday June 4, at Kigali International Airport as a three-month pilot with five dogs acquired from Police Dogs Centre Holland B.V, which supplies working dogs and related services to police, customs and security companies all over the world.

Rwanda says sniffer dogs will reduce the time and cost of testing at the Kigali International Airport. The Rwanda Biomedical Center says it has plan to scale up the use of sniffer dogs at mass gatherings based on the outcomes of this pilot phase, a partnership between Rwanda and Germany.

Germany supplied the Detection Dog Training System from Kynoscience, a German firm that also trained the dog handlers from the Canine Brigade of the Rwanda National Police.

It is believed that dogs can distinguish between more than a million different smells, they can detect even the finest traces of scent, and just a few molecules are enough for them to smell a substance.

In July 2020, researchers from Germany trained army sniffer dogs to distinguish between samples of fluids from patients infected with SARS-CoV-2 and healthy donors.

In this particular study, the researchers under the leadership of Dr. Esther Schalke, a vet at Germany’s armed forces school for service dogs and Prof. Holger Volk, Department Chair for Small Animal Diseases of Hanover’s University of Veterinary Medicine trained eight Bundeswehr (German Army) detection dogs over the period of a week to detect the saliva and secretions from the lungs and windpipe of patients who had been infected with SARS-CoV-2.

The 1st Secretary of the Germany Embassy in Rwanda, Renate Charlotte Lehner, said that Rwanda reach out to Germany to try the dogs in the effort to contain the spread of the coronavirus and create a solid foundation for future studies to investigate what the dogs smell and whether they can also be used to differentiate between different times of illness or clinical phenotypes.

The dog expert, Hans Ebbers, who is also CEO of Kynoscience, says there is no special breed but certain dogs are more talented.

Continue Reading

Health

AstraZeneca, COVAX Team Up to Get More Vaccines to Africa

Published

on

AstraZeneca a British-Swedish multinational pharmaceutical and biotechnology company has said it plans to get more covid-19 vaccines on the African continent as the fight against the pandemic intensifies.

The World Health Organisation (WHO) recently said Africa is in urgent need of 20 million doses to be able to administer the second jab to people that were inoculated.

Most African countries have been accessing vaccines against corona virus through COVAX a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations, and the World Health Organization.

However, the vaccines reaching the continent are insufficient- this is the reason AstraZeneca is teaming up with COVAX to find a quick solution.

“We agree completely with our partners at WHO that the supply of Covid-19 vaccines to African nations has reached a critical point,” says Barbara Nel, Africa region Country President, AstraZeneca.

She noted that the question for everyone in the vaccine alliance now is how we work together to try to make up the shortfall and get more doses to Africa.

AstraZeneca vaccines account for 97% of COVAX supply to date, with more than 71 million doses delivered to 125 participating countries, including more than 38 African countries.

Globally, more than 400 Million of AstraZeneca COVID-19 vaccines have been supplied to date.

Rwanda on May 27th received an extra 247,000 doses of the AstraZeneca. ” This consignment to Rwanda demonstrates the value of governments, industry and others working together to address our continent’s urgent needs,” Barbara Nel told Taarifa.

She added that all partners in the vaccine alliance are working round the clock to ensure that as many COVID-19 vaccines can get to African nations as soon as possible.   

“This is wonderful news for the people of Rwanda. On behalf of AstraZeneca, I would like to thank President Paul Kagame, President Emmanuel Macron of France and our partners at the COVAX coalition, the World Health Organization, Gavi, CEPI and UNICEF for making this possible.

According to Barbara Nel, extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures.

AstraZeneca has risen to the challenge of creating a not-for-profit vaccine that is widely available around the world and we are proud that our COVID-19 vaccine accounts for 96% of all supplies to COVAX.

To make wide vaccine access a reality, “we have established 20 supply lines over the last year, spread across the globe and have shared the IP and know-how with dozens of partners, one of which is SII, the largest vaccine manufacturer globally and the main supplier to Africa,” Barbara Nel said.

She added that their model is similar to what an open IP model could look like. “We will continue working in partnership with other manufacturers, governments and public health experts in all parts of the world in order to provide broad and equitable access to vaccines around the world.”

Last week, while on a state visit to Rwanda, French President Emmanuel Macron donated 247,000 doses of AstraZeneca vaccines to Rwanda.

“I want to thank you for coming along with much needed vaccines. We needed them very badly…that’s what friends are there for,” President Paul Kagame said during a joint press briefing.

Rwanda needs at least 13 million doses of Covid-19 vaccine to inoculate its target 60 percent of the population, about 7.5 million people, by June 2022.

So far, only 4% have received the first dose of the vaccine. Currently, delivery of the second doses of AstraZeneca vaccines to Kigali is experiencing delays after India suspended vaccine exports due to an upsurge in domestic Covid-19 cases.

Rwanda was to receive Covid-19 vaccines in early April from the Serum Institute of India via the Covax Facility. In March, Rwanda vaccinated 350,465 people, with the AstraZeneca and Pfizer vaccines.

Continue Reading
Advertisement

Canal+ Advert

Canal+ Advert
Advertisement
Advertisement
Advertisement

Trending